IndiaFilingsIndiaFilings
India FlagRegister India Company
UAE FlagRegister UAE Company
USA FlagRegister USA Company

PEARLESCENCE PHARMA LLP

LLPIN : ACV-2059|ROC: RoC-Mumbai-IIActive
Last Updated On : 03-03-2026
LLPINACV-2059
LLP NamePEARLESCENCE PHARMA LLP
Number of Partners2
Number of Designated Partners2
ROC CodeRoC-Mumbai-II
Date of Incorporation09-02-2026
Registered AddressS. NO. 649A120A PLOT NO. 09 FIRST TO FOUTRH Gole Colony Nashik Nashik Maharashtra India 422002
Email IDpearlescencepharma2026@gmail.com
Total Obligation of Contribution1,00,000
Main division of business activity to be carried out in India47
Description of main divisionRETAIL TRADE, EXCEPT OF MOTOR VEHICLES AND MOTORCYCLES
LLP StatusActive

Directors / Signatory Details

DIN / PANNameBegin Date
07575970KAVITA KUNAL DARADE09-02-2026
01948943KUNAL NARENDRA DARADE09-02-2026
PEARLESCENCE PHARMA LLP is a Limited Liability Partnership (LLP) governed by the LLP Act, 2008. Registered under the Registrar of Companies RoC-Mumbai-II, it operates as a non-government entity. According to the Ministry of Corporate Affairs (MCA), this LLP was incorporated on 09-02-2026 and last updated on 03-03-2026. Its LLP Identification Number (LLPIN) is , and the registration number is . Currently, its eFiling status is listed as “Active” as per MCA records.
From a financial standpoint, PEARLESCENCE PHARMA LLP has a total contribution of INR 1,00,000. Details of the latest financial filings, such as the Statement of Accounts and Solvency or Annual Returns, are unavailable, indicating limited publicly disclosed financial data.
The registered office address is S. NO. 649A120A PLOT NO. 09 FIRST TO FOUTRH Gole Colony Nashik Nashik Maharashtra India 422002. Correspondence or inquiries may be sent to the official email address, pearlescencepharma2026@gmail.com.
For those interested in further details, below are some frequently asked questions:
Disclaimer

IndiaFilings is not affiliated with any companies listed on this website and does not represent them. Please contact the respective company directly for their inquiries.